India Glycols Limited has informed the Exchange regarding 'Outcome of the Board Meeting'.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Glycols Limited reported strong full-year results for FY 2025-26 (year ended March 31, 2026). Standalone revenue grew 8.7% to Rs 9,826.20 Crores from Rs 9,037.82 Crores, while EBITDA improved significantly to Rs 690.09 Crores from Rs 521.34 Crores (32.4% growth). Profit after tax surged 56.5% to Rs 282.33 Crores versus Rs 180.38 Crores in the prior year. The company raised Rs 466.99 Crores through a preferential equity share issue at Rs 915 per share, completed a stock split from Rs 10 to Rs 5 face value, and declared an interim dividend of Rs 7.50 per share. The auditors issued an unmodified (clean) opinion on the financial statements. The Board also continued progressing a demerger scheme to separate the Bio Pharma and Spirits & Biofuel businesses.
The strong PAT growth of 56.5% and EBITDA margin improvement indicate operational efficiency gains. The clean audit and positive cash flows from operations (Rs 768.99 Crores) are positive signals for shareholders. The ongoing demerger and recent fund raise may lead to re-rating of the stock.